Skip to main navigation
Skip to search
Skip to main content
University of Birmingham Home
Help & FAQ
Link opens in a new tab
Search content at University of Birmingham
Home
Research output
Profiles
Research units
Projects
Activities
Datasets
Equipment
Prizes
Press/Media
Pharmacotherapy for obesity
M Li
, Bernard Cheung
Research output
:
Contribution to journal
›
Article
72
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Pharmacotherapy for obesity'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacotherapy
100%
Tetrahydrolipstatin
100%
Sibutramine
100%
Rimonabant
100%
Diarrhea
50%
Clinical Trial
50%
Receptor Antagonist
50%
Side Effect
50%
Diabetes Mellitus
50%
Heart Disease
50%
Dyslipidemia
50%
Adrenergic Receptor Stimulating Agent
50%
Esterase Inhibitor
50%
Sleep Disordered Breathing
50%
Antiobesity Drugs
50%
Endocannabinoid
50%
Flatulence
50%
Keyphrases
Obesity
100%
Pharmacotherapy
100%
Orlistat
50%
Sibutramine
50%
Rimonabant
50%
Anti-obesity
50%
European Medicines Agency
50%
Type 1 Diabetes Mellitus (T1DM)
25%
Gastrointestinal
25%
Diarrhea
25%
Hypertension
25%
Food Intake
25%
Receptor Antagonist
25%
Obese Patients
25%
Heart Disease
25%
Lifestyle Modification
25%
Long-term Efficacy
25%
Long-term Safety
25%
Dyslipidemia
25%
Neuropsychiatric Adverse Events
25%
Fat Absorption
25%
Clinical Trial Data
25%
Obstructive Sleep Apnea
25%
Flatulence
25%
Overweight Patient
25%
Serotonergic Drugs
25%
Developing Heart
25%
Lipase Inhibitor
25%
Adrenergic Drugs
25%
Committee for Medicinal Products for Human Use
25%
Endocannabinoid Receptors
25%